MA53881A - Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 - Google Patents

Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2

Info

Publication number: MA53881A
Authority: MA; Morocco
Prior art keywords: idh1; oxazin; pyrido; inhibitors; derivatives
Prior art date: 2016-12-16

Application number

MA053881A

Other languages

English (en)

Inventor

Renato Alejandro Bauer

Serge Louis Boulet

Timothy Paul Burkholder

Raymond Gilmour

Patric James Hahn

Zoran Rankovic

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-16

Filing date

2017-12-08

Publication date

2022-04-27

2017-12-08 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2022-04-27 Publication of MA53881A publication Critical patent/MA53881A/fr

Links

101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 title 1
101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 title 1
101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 title 1
102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 title 1
102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
UAQLXVHFTVTPBK-UHFFFAOYSA-N pyrido[4,3-d][1,3]oxazin-2-one Chemical class N=1C(OC=C2C=1C=CN=C2)=O UAQLXVHFTVTPBK-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MA053881A 2016-12-16 2017-12-08 Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 MA53881A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662435283P	2016-12-16	2016-12-16

Publications (1)

Publication Number	Publication Date
MA53881A true MA53881A (fr)	2022-04-27

Family

ID=60888651

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA053881A MA53881A (fr)	2016-12-16	2017-12-08	Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA47399A MA47399B1 (fr)	2016-12-16	2017-12-08	Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA47399A MA47399B1 (fr)	2016-12-16	2017-12-08	Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2

Country Status (37)

Country	Link
US (3)	US11001596B2 (fr)
EP (2)	EP3555105B1 (fr)
JP (1)	JP6793836B2 (fr)
KR (1)	KR102276022B1 (fr)
CN (2)	CN115109075B (fr)
AU (2)	AU2017378060B2 (fr)
CA (1)	CA3045303C (fr)
CL (1)	CL2019001551A1 (fr)
CO (1)	CO2019005287A2 (fr)
CR (1)	CR20190252A (fr)
CY (1)	CY1123577T1 (fr)
DK (1)	DK3555105T3 (fr)
DO (1)	DOP2019000163A (fr)
EA (1)	EA036112B1 (fr)
EC (1)	ECSP19042682A (fr)
ES (2)	ES2835281T3 (fr)
HR (1)	HRP20201882T1 (fr)
HU (1)	HUE052067T2 (fr)
IL (1)	IL267236B (fr)
JO (1)	JOP20190142B1 (fr)
LT (1)	LT3555105T (fr)
MA (2)	MA53881A (fr)
MD (1)	MD3555105T2 (fr)
MX (1)	MX385562B (fr)
MY (1)	MY197313A (fr)
NZ (1)	NZ754115A (fr)
PE (1)	PE20190977A1 (fr)
PH (1)	PH12019501328B1 (fr)
PL (1)	PL3555105T3 (fr)
PT (1)	PT3555105T (fr)
RS (1)	RS61108B1 (fr)
SA (1)	SA519401897B1 (fr)
SI (1)	SI3555105T1 (fr)
TN (1)	TN2019000158A1 (fr)
UA (1)	UA123640C2 (fr)
WO (1)	WO2018111707A1 (fr)
ZA (1)	ZA201903125B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9771349B2 (en)	2014-09-19	2017-09-26	Forma Therapeutics, Inc.	Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
MX372986B (es)	2014-09-19	2020-03-31	Forma Therapeutics Inc	Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
AU2015317322B2 (en)	2014-09-19	2020-09-17	Forma Therapeutics, Inc.	Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
LT3194376T (lt)	2014-09-19	2019-02-25	Forma Therapeutics, Inc.	Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitratdehidrogenazės inhibitoriai
US9624216B2 (en)	2015-04-21	2017-04-18	Forma Therapeutics, Inc.	Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US9624175B2 (en)	2015-04-21	2017-04-18	Forma Therapeutics, Inc.	Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
LT3640251T (lt)	2016-10-24	2022-03-10	Astrazeneca Ab	6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui
AU2017377069B2 (en)	2016-12-16	2020-07-23	Janssen Pharmaceutica Nv	Small molecule inhibitors of the JAK family of kinases
JOP20190144A1 (ar)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EP3555105B1 (fr) *	2016-12-16	2020-10-28	Eli Lilly and Company	Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MX2019008438A (es)	2017-01-30	2019-10-30	Astrazeneca Ab	Moduladores del receptor de estrogeno.
US11013734B2 (en)	2018-05-16	2021-05-25	Forma Therapeutics, Inc.	Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en)	2018-05-16	2021-05-25	Forma Therapeutics, Inc.	Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US20210196701A1 (en)	2018-05-16	2021-07-01	Forma Therapeutics, Inc.	Inhibiting mutant idh-1
WO2019222551A1 (fr)	2018-05-16	2019-11-21	Forma Therapeutics, Inc.	Formes solides de ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl) éthyl)amino)-1-méthyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11311527B2 (en)	2018-05-16	2022-04-26	Forma Therapeutics, Inc.	Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
TW202016110A (zh)	2018-06-15	2020-05-01	比利時商健生藥品公司	Ｊａｋ激酶家族之小分子抑制劑
US12521395B2 (en)	2019-11-08	2026-01-13	Nerviano Medical Sciences S.R.L.	Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors
WO2021194953A1 (fr)	2020-03-23	2021-09-30	Eli Lilly And Company	Procédé de traitement de sujets résistants à l'inhibiteur de l'idh1
BR112022017394A2 (pt)	2020-03-23	2022-10-18	Lilly Co Eli	Terapia de combinação com um inibidor de idh mutante
AU2021241470B2 (en) *	2020-03-23	2023-12-14	Board Of Regents, The University Of Texas System	Combination therapy with a mutant IDH inhibitor and a Bcl-2 inhibitor
IL297216A (en)	2020-04-24	2022-12-01	Astrazeneca Ab	Dosage regimen for the treatment of cancer
JP7719796B2 (ja)	2020-04-24	2025-08-06	アストラゼネカ・アクチエボラーグ	医薬製剤
US12559505B2 (en)	2020-06-28	2026-02-24	Wigen Biomedicine Technology (shanghai) Co., Ltd.	IDH mutant inhibitor and use thereof
EP4181927A1 (fr) *	2020-07-20	2023-05-24	Eli Lilly and Company	Polythérapie avec un inhibiteur d'idh1 mutant, un analogue de désoxyadénosine et un agent à base de platine
AU2022233254A1 (en)	2021-03-11	2023-10-26	Janssen Pharmaceutica Nv	Lorpucitinib for use in the treatment of jak mediated disorders
CN113588768B (zh) *	2021-05-18	2022-07-05	国家卫生健康委科学技术研究所	一种以分子图像方式定量组织内内源性代谢物的质谱方法
EP4337217A1 (fr)	2021-06-09	2024-03-20	Eli Lilly and Company	Procédé de traitement de sujets résistants à l'inhibiteur de l'idh
CA3217608A1 (fr)	2021-06-15	2022-12-22	Yuli Xie	Inhibiteur de mutant d'idh et son utilisation
WO2023018955A1 (fr)	2021-08-13	2023-02-16	Eli Lilly And Company	Formes solides de 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2-énoylpipérazin-1-yl)éthyl]phényl]éthyl]amino]-1-éthyl-4h-pyrimido[4,5-d][1,3]oxazin-2-one
WO2023141087A1 (fr)	2022-01-19	2023-07-27	Eli Lilly And Company	Polythérapie avec un inhibiteur d'idh mutant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2771337B1 (fr)	2011-09-27	2017-08-02	Novartis AG	3-(pyrimidin-4-yl)-oxazolidin-2-ones comme inhibiteurs d'idh mutante
BR112015022483A2 (pt) *	2013-03-14	2017-07-18	Novartis Ag	3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
WO2014147586A1 (fr) *	2013-03-22	2014-09-25	Novartis Ag	1-(2-(éthylamino)pyrimidin-4-yl)pyrrolidin-2-ones en tant qu'inhibiteurs du mutant idh
US9624175B2 (en) *	2015-04-21	2017-04-18	Forma Therapeutics, Inc.	Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CN107405687A (zh) *	2015-04-24	2017-11-28	哈利伯顿能源服务公司	制作陶瓷或金属间化合物零件的方法
US10253041B2 (en) *	2015-07-27	2019-04-09	Eli Lilly And Company	7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
CN109311863B (zh) *	2016-06-06	2021-10-29	伊莱利利公司	突变型idh1抑制剂
EP3555105B1 (fr) *	2016-12-16	2020-10-28	Eli Lilly and Company	Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2

2017
- 2017-12-08 EP EP17822882.1A patent/EP3555105B1/fr active Active
- 2017-12-08 HR HRP20201882TT patent/HRP20201882T1/hr unknown
- 2017-12-08 MX MX2019006830A patent/MX385562B/es unknown
- 2017-12-08 CA CA3045303A patent/CA3045303C/fr active Active
- 2017-12-08 ES ES17822882T patent/ES2835281T3/es active Active
- 2017-12-08 PE PE2019001077A patent/PE20190977A1/es unknown
- 2017-12-08 MA MA053881A patent/MA53881A/fr unknown
- 2017-12-08 JO JOP/2019/0142A patent/JOP20190142B1/ar active
- 2017-12-08 JP JP2019532088A patent/JP6793836B2/ja active Active
- 2017-12-08 PT PT178228821T patent/PT3555105T/pt unknown
- 2017-12-08 NZ NZ754115A patent/NZ754115A/en unknown
- 2017-12-08 RS RS20201429A patent/RS61108B1/sr unknown
- 2017-12-08 CN CN202210758386.7A patent/CN115109075B/zh active Active
- 2017-12-08 AU AU2017378060A patent/AU2017378060B2/en active Active
- 2017-12-08 TN TNP/2019/000158A patent/TN2019000158A1/en unknown
- 2017-12-08 DK DK17822882.1T patent/DK3555105T3/da active
- 2017-12-08 ES ES20189241T patent/ES2941631T3/es active Active
- 2017-12-08 MD MDE20191188T patent/MD3555105T2/ro unknown
- 2017-12-08 MY MYPI2019003350A patent/MY197313A/en unknown
- 2017-12-08 KR KR1020197016855A patent/KR102276022B1/ko active Active
- 2017-12-08 CR CR20190252A patent/CR20190252A/es unknown
- 2017-12-08 HU HUE17822882A patent/HUE052067T2/hu unknown
- 2017-12-08 PH PH1/2019/501328A patent/PH12019501328B1/en unknown
- 2017-12-08 UA UAA201905584A patent/UA123640C2/uk unknown
- 2017-12-08 CN CN201780078017.0A patent/CN110072867B/zh active Active
- 2017-12-08 LT LTEP17822882.1T patent/LT3555105T/lt unknown
- 2017-12-08 PL PL17822882T patent/PL3555105T3/pl unknown
- 2017-12-08 EP EP20189241.1A patent/EP3763717B1/fr active Active
- 2017-12-08 WO PCT/US2017/065246 patent/WO2018111707A1/fr not_active Ceased
- 2017-12-08 EA EA201991161A patent/EA036112B1/ru not_active IP Right Cessation
- 2017-12-08 MA MA47399A patent/MA47399B1/fr unknown
- 2017-12-08 SI SI201730488T patent/SI3555105T1/sl unknown
- 2017-12-08 US US16/349,873 patent/US11001596B2/en active Active
2019
- 2019-05-17 ZA ZA2019/03125A patent/ZA201903125B/en unknown
- 2019-05-23 CO CONC2019/0005287A patent/CO2019005287A2/es unknown
- 2019-05-30 SA SA519401897A patent/SA519401897B1/ar unknown
- 2019-06-06 CL CL2019001551A patent/CL2019001551A1/es unknown
- 2019-06-11 DO DO2019000163A patent/DOP2019000163A/es unknown
- 2019-06-11 IL IL267236A patent/IL267236B/en active IP Right Grant
- 2019-06-14 EC ECSENADI201942682A patent/ECSP19042682A/es unknown
2020
- 2020-10-29 AU AU2020260493A patent/AU2020260493B2/en active Active
- 2020-11-25 CY CY20201101122T patent/CY1123577T1/el unknown
2021
- 2021-03-16 US US17/202,867 patent/US11629156B2/en active Active
- 2021-03-16 US US17/202,515 patent/US11649247B2/en active Active

Also Published As

Publication number	Publication date
PH12019501328A1 (en)	2020-02-24
PT3555105T (pt)	2020-12-21
PL3555105T3 (pl)	2021-05-17
EA201991161A1 (ru)	2019-11-29
CN110072867A (zh)	2019-07-30
MY197313A (en)	2023-06-13
ECSP19042682A (es)	2019-06-30
AU2020260493A1 (en)	2020-11-26
CN110072867B (zh)	2022-07-08
MX385562B (es)	2025-03-18
MA47399B1 (fr)	2021-02-26
AU2017378060A1 (en)	2019-05-30
CL2019001551A1 (es)	2019-10-25
RS61108B1 (sr)	2020-12-31
AU2020260493B2 (en)	2021-09-09
CA3045303C (fr)	2022-05-17
EA036112B1 (ru)	2020-09-29
EP3555105B1 (fr)	2020-10-28
HUE052067T2 (hu)	2021-04-28
HRP20201882T1 (hr)	2021-01-22
ES2941631T3 (es)	2023-05-24
CY1123577T1 (el)	2022-03-24
JOP20190142A1 (ar)	2019-06-13
JP2020502157A (ja)	2020-01-23
US20200079791A1 (en)	2020-03-12
US20210230185A1 (en)	2021-07-29
MD3555105T2 (ro)	2021-01-31
IL267236A (en)	2019-08-29
PH12019501328B1 (en)	2023-05-12
CA3045303A1 (fr)	2018-06-21
CR20190252A (es)	2019-08-26
SA519401897B1 (ar)	2022-07-28
KR102276022B1 (ko)	2021-07-13
DK3555105T3 (da)	2020-11-09
WO2018111707A1 (fr)	2018-06-21
EP3763717B1 (fr)	2023-03-08
EP3763717A1 (fr)	2021-01-13
JP6793836B2 (ja)	2020-12-02
US11629156B2 (en)	2023-04-18
EP3555105A1 (fr)	2019-10-23
CO2019005287A2 (es)	2019-05-31
CN115109075A (zh)	2022-09-27
US11649247B2 (en)	2023-05-16
PE20190977A1 (es)	2019-07-09
IL267236B (en)	2020-08-31
TN2019000158A1 (en)	2020-10-05
UA123640C2 (uk)	2021-05-05
ES2835281T3 (es)	2021-06-22
SI3555105T1 (sl)	2020-12-31
JOP20190142B1 (ar)	2023-03-28
NZ754115A (en)	2021-07-30
CN115109075B (zh)	2024-09-20
DOP2019000163A (es)	2019-07-15
ZA201903125B (en)	2024-08-28
MA47399A (fr)	2019-10-23
MX2019006830A (es)	2019-08-22
LT3555105T (lt)	2021-01-11
BR112019009648A2 (pt)	2019-09-10
US11001596B2 (en)	2021-05-11
US20210206780A1 (en)	2021-07-08
KR20190077539A (ko)	2019-07-03
AU2017378060B2 (en)	2020-09-03

Publication	Publication Date	Title
MA53881A (fr)	2022-04-27	Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA47123A (fr)	2021-03-17	Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA46981A (fr)	2019-10-09	Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EA201791692A1 (ru)	2018-01-31	4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
MA46470A (fr)	2019-08-14	1h-imidazo[4,5-b]pyridin-2(3h)-ones substituées et leur utilisation en tant que modulateurs du récepteur glun2b
MX390630B (es)	2025-03-21	Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
EP3416964A4 (fr)	2019-09-18	Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
IL263947B (en)	2022-10-01	Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof
MA45153A (fr)	2021-04-07	Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
HUE053027T2 (hu)	2021-06-28	Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra
MX386328B (es)	2025-03-18	Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MA41140A (fr)	2017-10-17	Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA46264A (fr)	2019-07-31	Dérivés pyrazolo[1,5-a]pyridine et leur utilisation en tant qu'agents de lutte antiparasitaire
ME03672B (fr)	2020-10-20	1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
EP3515914A4 (fr)	2020-04-15	Nouvelles imidazo[1,5-a]pyridines substituées en position 5 ou 8 en tant qu'indoleamine et/ou tryptophane 2,3-dioxygénases
EP3328379A4 (fr)	2019-06-19	Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
MA54448A (fr)	2021-10-20	Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
BR112017023432A2 (pt)	2018-07-24	Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
EP3380475A4 (fr)	2019-07-03	Dérivés d'octahydropyrrolo [3, 4-c
MX2018002416A (es)	2018-11-29	Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
EP3402793A4 (fr)	2019-10-09	Dérivés de pyridazine en tant qu'activateurs d'eaat2
EP3334719A4 (fr)	2019-02-06	Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
EP3487851A4 (fr)	2019-12-25	Dérivés de l'aminopyridine et leur utilisation en tant qu'inhibiteurs sélectifs d'alk-2
MA52722A (fr)	2021-04-14	Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
UY35747A (es)	2015-04-30	Derivados sustituidos de fenilalanina